Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis

Autor:	Hongbo He, Xiaojia Wen, Huyong Zheng
Jazyk:	angličtina
Rok vydání:	2024
Předmět:	Acute myeloid leukemia Venetoclax Azacitidine Decitabine Low-dose cytarabine Meta-analysis Diseases of the blood and blood-forming organs RC633-647.5
Zdroj:	Hematology, Vol 29, Iss 1 (2024)
Druh dokumentu:	article
ISSN:	16078454 1607-8454
DOI:	10.1080/16078454.2024.2343604
Popis:	Purpose: To explore the efficacy and safety of venetoclax-based combination therapy for older patients with newly diagnosed acute myeloid leukemia (AML).Methods: We performed a systematic review and meta-analysis of clinical trials comparing venetoclax plus hypomethylating agents (HMAs) or low-dose cytarabine (LDAC) with mono-HMAs or LDAC. The random or fixed effects model was applied to the studies based on heterogeneity. Dichotomous data were summarized using the risk ratio (RR) and 95% confidence interval (CI). Continuous variable data were reported as weighted mean differences (WMDs).Results: Nine studies, including a total of 1232 patients, were included in this meta-analysis. Thec complete remission (CR)/complete remission with incomplete hematological recovery (CRi) rate of the venetoclax (Ven) + azacytidine (Aza) group was significantly greater than that of the Aza monotherapy group (RR: 2.42; 95% CI: 1.85–3.15; P
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/e456acd7cf7344bdbfd5785afe1d3f77 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.